Pfizer Launches Phase II Trial For Experimental Glaucoma Treatment In Japan
This article was originally published in PharmAsia News
Pfizer will expand the clinical development program for its experimental glaucoma treatment PF-03187207 by launching a Phase II trial in Japan, French partner NicOx announced Jan. 3
You may also be interested in...
NicOx and Pfizer reported more disappointing news related to their nitric-oxide donating prostaglandin analog candidate for glaucoma Aug. 25, noting the compound failed to meet its primary endpoint in a Japanese Phase II trial
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).